We can’t show the full text here under this license.
Abstract
Semaglutide may reduce major adverse cardiovascular events in overweight or obese patients with high cardiovascular risk.
- Semaglutide improves functional capacity in patients with heart failure and preserved left ventricular function.
- It could slow the progression of albuminuria in diabetic populations.
- There is a potential reduction in the risk of chronic kidney disease associated with semaglutide.
- The drug's effects may stem from its anti-inflammatory properties and ability to lower blood pressure.
- Weight reduction is another mechanism through which semaglutide may enhance cardiovascular and renal health.
Simplified